Rationale: The overall rationale for all microbicide trials is to identify products that could be used vaginally or rectally to help reduce the user's risk of HIV infection. These candidates could be formulated in many ways including as gels, suppositories, creams, and vaginal rings. In laboratory tests, Carraguard was effective at blocking infected cells from non-infected cells. Its specific mechanism of action is unknown.
Study Questions: This study was designed to examine whether the microbicide Carraguard could protect women against HIV if used consistently and correctly before sex; whether it is safe for use; and whether correct and consistent gel use reduces risk of infection with other sexually transmitted infections.
Participants: 6,299 HIV-negative women
Country: South Africa
Trial sponsors and collaborators: Bill & Melinda Gates Foundation, Population Council, United States Agency for International Development (USAID)
When were results released? Results were announced February 2008. There was no evidence of benefit.
To learn more visit:
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2808%2961842-5/abstract
http://www.popcouncil.org/mediacenter/newsreleases/Carraguard_Findings.html
http://www.avac.org/pdf/mira_carraguard.pdf